Illumina, Inc.

Illumina, Inc. is an American biotechnology company headquartered in San Diego, California, founded in 1998. It is a publicly traded company on Nasdaq under the ticker ILMN. As of 2024, Illumina reported approximately 8,970 employees and a revenue of $4.37 billion.

Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its product lines and services serve the sequencing, genotyping, and gene expression markets. Key offerings include DNA sequencing systems like NovaSeq, HiSeq, MiSeq, and NextSeq, as well as microarray-based products, library preparation kits, software for data analysis, and various genomic services. The company's customer base includes genomic research centers, pharmaceutical companies, academic institutions, and clinical research organizations globally.

Illumina has an active patent litigation posture, generally asserting its intellectual property. The company's patent strategy involves both protecting its own technologies and engaging in strategic licensing and partnerships. The provided case data indicates Illumina, Inc. has appeared as a plaintiff in one tracked case in the U.S. District Court for the District of Delaware and has no defendant cases in this dataset. This aligns with a posture of an operating company asserting its patent portfolio.

A notable case for Illumina, Inc. is Illumina, Inc. v. Guardant Health, Inc., where Illumina is the plaintiff in the U.S. District Court for the District of Delaware. This is consistent with Illumina's history of utilizing litigation to safeguard its intellectual property and market position. Illumina has been involved in several significant patent disputes in the past, including cases against Ariosa Diagnostics and BGI Genomics, often centered around DNA sequencing technologies.